# LENZ THERAPEUTICS, INC. (LENZ) · Edgar & Edgarette company card

> Lenz Therapeutics (LENZ) reported revenue of $19 million in FY2025, operating margin -477% against a -15.8% median for biological products, (no diagnostic substances), equity 93.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1815776 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/LENZ) · [JSON](https://www.pops4.com/boards/company/LENZ.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $19M |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -477.5% (prior year -Infinity%) |
| Net margin | -430.3% |
| Operating cash flow | −$69M |
| Capital spending | $827,000 |
| Free cash flow | −$70M |
| Cash | $25M |
| Long-term debt | — |
| Total assets | $306M |
| Total equity | $284M |
| Equity ÷ assets | 93.0% |
| Return on equity | -28.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 15.45 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative

## Edgarette's reading

Exposure: revenue $19.1M (FY2025). Experience: one year on record; operating margin -477.5%, up from null. Soundness: equity 93.0% of assets, return on equity -28.9%. Credibility: 2 audited years, moderate weight. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -477.5% against a -15.8% median.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-10-28 ([filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/0001815776-26-000056-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-10-28 ([filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/0001815776-26-000056-index.htm))

## Recent filings

- 8-K · filed 2026-10-28 · 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/0001815776-26-000056-index.htm)
- 10-Q · filed 2026-08-11 · [filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000052/0001815776-26-000052-index.htm)
- 8-K · filed 2026-08-11 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000051/0001815776-26-000051-index.htm)
- 8-K · filed 2026-07-02 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000046/0001815776-26-000046-index.htm)
- 8-K · filed 2026-06-12 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000041/0001815776-26-000041-index.htm)
- 10-Q · filed 2026-05-11 · [filing](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000037/0001815776-26-000037-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001815776.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1815776

## Cite

POPS4, Edgar & Edgarette: LENZ THERAPEUTICS, INC. (LENZ) company card, from the company's own SEC filings, accessed 2026-10-29, https://www.pops4.com/boards/company/LENZ. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.